Text Size

Daily Monitoring of Exhaled Nitric Oxide in Asthmatic Patients

This study has been completed.
Sponsor:
Collaborator:
Azienda Ospedaliera Universitaria Policlinico
Information provided by:
Universita di Verona
ClinicalTrials.gov Identifier:
NCT01113853
First received: April 28, 2010
Last updated: April 30, 2010
Last verified: January 2007
History of Changes
  Purpose

Previous studies have demonstrated that exhaled nitric oxide can be useful to monitor the efficacy of anti-inflammatory treatment as well as to predict a risk of asthma relapse in asthmatic patients.

The aim of the present study is to evaluate the time course of exhaled nitric oxide in mild asthmatic patients, stopping regular treatment with inhaled corticosteroids, if it is possible, in relationship with symptoms and lung function.


Condition
Asthma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Daily Monitoring of Exhaled Nitric Oxide in Asthmatic Patients Stopping Anti-inflammatory Treatment

Resource links provided by NLM:

MedlinePlus related topics: Asthma
U.S. FDA Resources

Further study details as provided by Universita di Verona:

Enrollment: 40
Study Start Date: January 2007
Study Completion Date: January 2010
Detailed Description:

All patients were evaluated with pulmonary lung function, exhaled nitric oxide and peak expiratory flow (PEF) and fill in a personal diary for the first two weeks when patients are in treatment; the same evaluation will be made for other four weeks without treatment.

  Eligibility

Ages Eligible for Study:   5 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

children with asthma visited in the outpatients clinic at University of Verona were invited to participate to the study

Criteria

Inclusion Criteria:

  • mild asthmatic treated with low dose inhaled steroids for whom it has to be considered stop of steroid treatment according to GINA guidelines

Exclusion Criteria:

  • age < 5 years
  • chronic respiratory diseases
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01113853

Locations
Italy
Pediatric Department University of Verona
Verona, Italy, 37100
Sponsors and Collaborators
Universita di Verona
Azienda Ospedaliera Universitaria Policlinico
Investigators
Principal Investigator: Giorgio L Piacentini, MD University of Verona
  More Information

No publications provided

Responsible Party: attilio L Boner, Università di Verona
ClinicalTrials.gov Identifier: NCT01113853     History of Changes
Other Study ID Numbers: AOV 1360
Study First Received: April 28, 2010
Last Updated: April 30, 2010
Health Authority: Italy: National Bioethics Committee

Keywords provided by Universita di Verona:
asthma
exhaled nitric oxide
lung function

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
 Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Cardiovascular Agents
Protective Agents

ClinicalTrials.gov processed this record on June 18, 2013